Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials

Michael Shaw1 email, John Dent2 email, Timothy Beebe3 email, Ola Junghard4 email, Ingela Wiklund4 email, Tore Lind4 email and Folke Johnsson5 email

1Park Nicollet Clinic and University of Minnesota Medical School, Minneapolis, MN 55416-2699, USA

2Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia

3Mayo Clinic College of Medicine, Rochester, MN 55905, USA

4AstraZeneca R&D, SE-431 83 Mölndal, Sweden

5University of Lund, SE-221 00 Lund, Sweden

author email corresponding author email

Health and Quality of Life Outcomes 2008, 6:31doi:10.1186/1477-7525-6-31

Published: 30 April 2008

Abstract

Background

Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian.

Methods

Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor.

Results

The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89.

Conclusion

The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.


© 1999-2008 BioMed Central Ltd unless otherwise stated < info@biomedcentral.com >   Terms and conditions